Meclofenoxate therapy in tardive dyskinesia: a preliminary report.

Abstract

Tardive dyskinesia seems to occur as a result of diminished cholinergic and enhanced dopaminergic activity in the striatum. Meclofenoxate has been shown to increase cerebral cholinergic activity. To ameliorate the tardive dyskinesia, meclofenoxate was given orally, 600-1200 mg/day, for 6-12 weeks. The effects of the drug were evaluated by scoring the degree of involuntary movement. Among 11 subjects with tardive dyskinesia or dystonia, 4 improved markedly, 1 moderately, 2 slightly, and there was no improvement in 4. One patient with subacute oral dyskinesia, induced by administration of neuroleptics for 1 month, improved markedly. The possibility that meclofenoxate may be effective in dealing with dyskinesias that are induced by neuroleptics warrants further attention.

• Authors: K Izumi, H Tominaga, T Koja, M Nomoto, T Shimizu, H Sonoda, K Imamura, A Igata, T Fukuda
• Journal: Biological psychiatry (Biol Psychiatry) Vol. 21 Issue 2 Pg. 151-60 (Feb 1986) ISSN: 0006-3223 [Print] United States
• PMID: 2868761 (Publication Type: Journal Article)

Chemical References

• Antipsychotic Agents
• Glycolates
• Meclofenoxate

Topics

• Administration, Oral
• Adult
• Aged
• Antipsychotic Agents (adverse effects, therapeutic use)
• Bipolar Disorder (drug therapy)
• Dyskinesia, Drug-Induced (drug therapy)
• Electromyography
• Female
• Glycolates (therapeutic use)
• Humans
• Male
• Meclofenoxate (therapeutic use)
• Middle Aged
• Schizophrenia (drug therapy)